All In Biotech

Drug Trial Radar · NCT00958581

Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery

A Prospective, Randomized, Double-blinded Single-site Control Study Comparing Blood Loss Prevention of Tranexamic Acid (TXA) to Epsilon Aminocaproic Acid (EACA) for Corrective Spinal Surgery

Last checked: Nov 20, 2026Latest source record: Jan 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 177 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

177

Actual

Start

Dec 2008

Primary completion

Sep 2012

Study completion Sep 2012

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 13, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tranexamic acid (TXA) and epsilon aminocaproic acid (EACA) have been reported to reduce blood loss in the cardiac surgery literature but they have not been reported in use head-to-head in the orthopedic surgery literature. In a randomized, double-blind, prospective study we believe that TXA will be more effective than both EACA and placebo at reducing blood loss for corrective spinal surgery.

Conditions

  • Scoliosis

Interventions

  • Tranexamic AcidDrug

    For TXA, the loading dose is 10mg/kg infused over 15 minutes, while the maintenance dose is 1/mg/kg hr.

  • Normal SalineDrug

    Normal saline of same volume as the intervention group will be given as the intervention group as a loading dose and maintenance dose.

  • Epsilon aminocaproic acidDrug

    For EACA, the loading dose is 100mg/kg infused over 15 minutes, while the maintenance dose is 10mg/kg hr.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Blood Loss Over Course of Stay (Intraoperative and Postoperatively Until Discharge)Time frame: 1 Week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New York University School of Medicine - Department of Orthopaedic Surgery - Spine

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.